Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

New England Journal of Medicine

Volumn 353, Issue 12, 2005, Pages 1209-1223

  Lieberman, Jeffrey A ^a   Scott Stroup, T ^b   McEvoy, Joseph P ^e,f   Swartz, Marvin S ^f   Rosenheck, Robert A ^g   Perkins, Diana O ^b   Keefe, Richard S E ^f   Davis, Sonia M ^c,d   Davis, Clarence E ^c   Lebowitz, Barry D ^h   Severe, Joanne ^h   Hsiao, John K ^h  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

^d IQVIA   (United States)

^e John Umstead Hospital   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; HYPNOTIC AGENT; INSULIN; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; LIPID; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AKATHISIA; AROUSAL; ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOOD AND DRUG ADMINISTRATION; GALACTORRHEA; GLUCOSE METABOLISM; GYNECOMASTIA; HUMAN; HYPERSOMNIA; INCONTINENCE; INSOMNIA; LIBIDO DISORDER; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; NOCTURIA; ORGASM; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; TREATMENT WITHDRAWAL; URINARY HESITANCY; WEIGHT GAIN; XEROSTOMIA; BLOOD; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG EFFECT; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHRONIC DISEASE; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPIDS; MALE; PATIENT COMPLIANCE; PERPHENAZINE; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 25144456112     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa051688     Document Type: Article

References (35)

1. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10:79-104.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
3. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
4. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
5. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 2001;155:230-3.
6. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
7. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9.
8. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22.
9. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9.
10. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26.
11. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56:1-10.
12. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-702.
13. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.
14. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-22.
15. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-8. [Erratum, Arch Gen Psychiatry 1998;55:1052.]
16. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22. [Erratum, N Engl J Med 2002;346:1424.]
17. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
18. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28.
19. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021-6.
20. Atypical antipsychotics - generating evidence to inform policy and practice. London: IMS Health, 2002. (Accessed August 26, 2005, at http://research.imshealth.com/research/research_schizophrenia.htm.)
21. Harrington C, Gregorian R, Gemmen E, et al. Access and utilization of new antidepressant and antipsychotic medications. Falls Church, Va.: Lewin Group, 2000. (Accessed August 26, 2005, at http://aspe.hhs.gov/search/health/reports/ Psychmedaccess/ index.htm#TOC.)
22. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624-32.
23. Lebowitz BD, Vitiello B, Norquist GS. Approaches to multisite clinical trials: the National Institute of Mental Health perspective. Schizophr Bull 2003;29:7-13.
24. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31.
25. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull 2003;29:33-43.
26. Keefe RS, Mohs RC, Bilder RM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull 2003;29:45-55.
27. Rosenheck R, Doyle J, Leslie D, Fontana A. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull 2003;29:81-93.
28. Davis SM, Koch GG, Davis CE, LaVange LM. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophr Bull 2003;29:73-80.
29. Cox DR. Regression models and lifetables. J R Stat Soc [B] 1972;34:187-220.
30. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
31. Rosenheck RA. Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 2005;56:85-92.
32. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002;10:280-91.
33. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208.
34. Intercontinental Medical Systems National Disease and Therapeutic Index. Plymouth Meeting, Pa.: IMS Health, January 2001-December 2004.
35. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:Suppl:1-56.